Table 4.
Summary of pyroptosis introductive treatment in other tumors.
| Treatment | Cancer Types | Mechanisms of Pyroptosis Induction | Reference |
|---|---|---|---|
| Galangin | Glioma | Caspase-3/GSDME | (90) |
| Dasatinib | Neuroblastoma | Caspase-3/GSDME GSDMD |
(92) |
| Doxoribici, BRAFi + MEKi, Etoposide |
Melanoma | Caspase-3/GSDME | (93, 94) |
| Iron + CCCP | Melanoma | ROS/Tom20/Bax/Caspase-3/GSDME | (27) |
| DHA | Breast cancer | Caspase-1/GSDMD/IL-1β | (96) |
| NP-GSDMA3 + Phe-BF3 | Breast cancer | GSDMA3 | (97) |
| Nobiletin | Ovarian cancer | ROS/Autophagy/GSDMD & GSDME | (98) |
| α-NETA | Ovarian cancer | Caspase-4/GSDMD | (99) |
| Tanshinone II A | Cervical cancer | miR145/GSDMD/IL-1β & IL-18 | (100) |
| SIRT1 knockdown | Cervical cancer | AIM2/Caspase-1 | (101) |
| Hydrogen | Endometrial cancer | ROS and Mitosox/NLRP3/Caspase-1/GSDMD/IL-1β | (102) |
| JQ1 | Renal cancer | NF-κB suppression/NLRP3/Caspase-1/GSDMD | (103) |
| 3’,5’-diprenylated chalcones | Prostate cancer | PKCδ/JNK/Mitochondrial apoptotic pathway/Caspase-3/GSDME | (38) |
| Taxol | Nasopharyngeal carcinoma | Caspase-1/GSDMD/IL-1 | (104) |
| Casticin | Nasopharyngeal carcinoma | PKR/JNK/NF-κb/Caspase-1/GSDMD | (105) |
| Lobaplatin | Nasopharyngeal carcinoma | cIAP1/2 suppression & Ripoptosome & ROS/Caspase-3/GSDME | (106) |
| Dioscin | Osteosarcoma | Caspase-3/GSDME | (107) |
| Anthocyanin | Oral squamous cell carcinoma | NLRP3/Caspase-1/GSDMD/IL-1β | (108) |
| Doxorubicin, Cisplatin |
Mesothelioma | NLRP3/Caspase-1 | (109) |